Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03766126 · ClinicalTrials.gov registry record · Phase 1
Lentivirally Redirected CD123 Autologous T Cells in AML
A Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03766126: Active Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, sponsored by University of Pennsylvania.
NCT03766126 is a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 22 participants, below the 58-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03766126, a Phase 1 study of Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute Myeloid Leukemia (AML) subjects.
Conditions Studied
Interventions
- BIOLOGICAL CART123 cells; cyclophosphamide; fludarabine
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2033-12-03 |
| Phase | Phase 1 |
What the registry record for NCT03766126 still lists
NCT03766126 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 58-participant average among 16 other Acute Myeloid Leukemia, in Relapse trials with a reported enrollment target (62% lower).
The record links to 3 conditions, with Acute Myeloid Leukemia, in Relapse appearing as the primary indexed condition, and to 1 intervention - of which CART123 cells; cyclophosphamide; fludarabine is the first listed.
NCT03766126 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03766126 about?
NCT03766126 is a clinical study titled "Lentivirally Redirected CD123 Autologous T Cells in AML". Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute Myeloid Leukemia (AML...
What is the current status of trial NCT03766126?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-12-06. Estimated completion is 2033-12-03.
What conditions does trial NCT03766126 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Adult.
What interventions are being tested in trial NCT03766126?
The interventions under investigation include: CART123 cells; cyclophosphamide; fludarabine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03766126?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03766126 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia, in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03766126's enrollment target sits among peer trials
22 11th of 16 higher than 6 of 16 other Acute Myeloid Leukemia, in Relapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia, in Relapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
RECRUITING · Phase 1
-
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
RECRUITING · Phase 1
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Venetoclax to Augment Epigenetic Modification and Chemotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI